Vernalis plc

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vernalis plc
Public company
Industry Biotechnology
Founded 2003
Headquarters Winnersh, United Kingdom
Key people
Ian Garland
Peter Fellner
(Executive chairman)
Products Frovatriptan, Apokyn
Number of employees

Vernalis plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]

The company has marketed two drug products; Frovatriptan,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]

The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono. It is listed on the London Stock Exchange and is a constituent of the FTSE Fledgling Index.


  1. ^ "Vernalis agrees £91m merger plan with British Biotech". Advances in Life Science. ALS. 2003. Retrieved 3 July 2003. 
  2. ^ "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 28 November 2007. 
  3. ^ "Patient Information Sheet – Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 29 September 2007. Retrieved 28 November 2007. 
  4. ^ "Apokyn". FDA. 2004. Retrieved 29 July 2004. [dead link]

External links[edit]